SynthesisBMC geriatrics2026
Immersive virtual reality for older adults with mild cognitive impairment, dementia, or cognitive frailty: a systematic review and narrative synthesis (2019-2025).
Synthesis in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmersive virtual reality (VR) is increasingly used to support cognition, mobility, and emotional well‑being in older adults with mild cognitive impairment (MCI), dementia, or frailty. Evidence is expanding but fragmented across small randomized and feasibility trials. We synthesized recent studies to clarify benefits, risks, and implementation considerations.
methodsFollowing PRISMA 2020, we searched PubMed and CINAHL from 1 January 2019 to 15 October 2025. Eligible studies enrolled adults aged ≥ 65 years with MCI, dementia, or frailty/cognitive frailty; delivered immersive or semi‑immersive VR via head‑mounted display or large‑screen projection (interactive tasks or 360° content); and reported cognitive, mobility, or emotional/behavioral outcomes in randomized, quasi‑experimental, or pre-post designs. Two reviewers independently screened and extracted data. Risk of bias was appraised with RoB 2 (randomized trials) or JBI tools (non‑randomized). Heterogeneity precluded meta‑analysis; we conducted a structured narrative synthesis.
resultsSeventy records were identified (PubMed 28; CINAHL 42); after removing 9 duplicates, 61 records were screened, 24 full texts were assessed, and 13 studies were included (10 randomized; 3 feasibility/mixed‑methods). The most consistent improvements occurred in executive function and processing speed among participants with MCI or cognitive frailty; several trials also reported modest gains in global cognition. Multiple trials showed better Timed Up & Go and Berg Balance outcomes and enhanced anticipatory postural adjustments versus comparators. In residential care, immersive reminiscence and group VR reduced anxiety and apathy and were well tolerated. Adverse events were uncommon and mild; adherence was high with supervised delivery. Most randomized trials had some concerns for bias; one was at overall low risk.
conclusionsImmersive and semi-immersive VR interventions appear feasible for supervised delivery in older adults with MCI or cognitive frailty and may be associated with improvements in cognitive and mobility outcomes. Evidence for emotional and behavioral outcomes in institutional settings is promising but preliminary. Programs with adequate exposure (2-3 sessions/week for 8-12 weeks; ≥ 15 total hours), adaptive challenge, and supervision were most frequently associated with positive outcomes. Larger multicenter randomized trials with standardized outcomes and embedded implementation and economic evaluations are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.